Barclays Maintains Overweight on Boston Scientific, Lowers Price Target to $89

Benzinga Newsdesk www.benzinga.com Negative 89.2%

Neg 89.2% Neu 0% Pos 0%

Barclays analyst Matt Miksic maintains Boston Scientific (NYSE:BSX) with a Overweight and lowers the price target from $96 to $89.